Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 11/20 | 0.51 |
| ▸ | KLK7 | P49862 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16857545 | 1.00 | FKBP1A (0.51) | FKBP1AKLK7POLBCTSLPARP1 | |
| SCHEMBL16857540 | 1.00 | FKBP1A (0.51) | FKBP1AKLK7POLBCTSLPARP1 | |
| SCHEMBL9949516 | 0.91 | POLB (0.49) | FKBP1AKLK7POLBCTSLAGTR2 | |
| SCHEMBL9949512 | 0.91 | POLB (0.49) | FKBP1AKLK7POLBCTSLAGTR2 | |
| SCHEMBL9296386 | 0.90 | POLB (0.53) | FKBP1AKLK7POLBCTSLPARP1 | |
| SCHEMBL17191527 | 0.90 | POLB (0.53) | FKBP1AKLK7POLBCTSLPARP1 | |
| SCHEMBL1150829 | 0.90 | POLB (0.53) | FKBP1AKLK7POLBCTSLPARP1 | |
| SCHEMBL1449334 | 0.90 | POLB (0.53) | FKBP1AKLK7POLBCTSLPARP1 | |
| SCHEMBL1783541 | 0.90 | POLB (0.53) | FKBP1AKLK7POLBCTSLPARP1 | |
| SCHEMBL1448453 | 0.90 | POLB (0.53) | FKBP1AKLK7POLBCTSLPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136591-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| US-20250082614-A1 | METHODS OF USING RAD51 INHIBITORS FOR TREATMENT OF PANCREATIC CANCER | CYTEIR THERAPEUTICS, INC. | 2025-03-13 | — | — | US | disclosed |
| CN-114514023-B | Methods of treating pancreatic cancer using RAD51 inhibitors | 赛泰尔治疗公司 | 2025-01-14 | — | — | CN | disclosed |
| US-12064419-B2 | Methods of using RAD51 inhibitors for treatment of pancreatic cancer | CYTEIR THERAPEUTICS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| CN-111542521-B | RAD51 inhibitors | 赛泰尔治疗公司 | 2024-02-23 | — | — | CN | disclosed |
| EP-4112616-A1 | RAD51 INHIBITORS | Cyteir Therapeutics, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-3681884-B1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS INC (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-3681884-B1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS INC (US) | 2022-06-01 | — | — | EP | disclosed |
| CN-114514023-A | Methods of treating pancreatic cancer using RAD51 inhibitors | 赛泰尔治疗公司 | 2022-05-17 | — | — | CN | disclosed |
| EP-3986402-A1 | METHODS OF USING RAD51 INHIBITORS FOR TREATMENT OF PANCREATIC CANCER | Cyteir Therapeutics, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| US-10590122-B2 | RAD51 inhibitors | CYTEIR THERAPEUTICS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-10336746-B1 | RAD51 inhibitors | CYTEIR THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20190194182-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190194182-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2019051465-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. (US) | 2019-03-14 | — | — | WO | disclosed |
| US-20190077799-A1 | RAD51 Inhibitors | CYTEIR THERAPEUTICS, INC. | 2019-03-14 | — | — | US | disclosed |
| EP-2889288-B1 | METHOD FOR PRODUCING cis-5-HYDROXY-2-PIPERIDINECARBOXYLIC ACID DERIVATIVE, AND METHOD FOR PURIFYING cis-5-HYDROXY-2-PIPERIDINECARBOXYLIC ACID | API CORP (JP) | 2018-07-25 | — | — | EP | disclosed |
| US-9981984-B2 | Method for producing cis-5-hydroxy-2-piperidinecarboxylic acid derivative, and method for purifying cis-5-hydroxy-2-piperidinecarboxylic acid | API CORPORATION (JP) | 2018-05-29 | — | — | US | disclosed |
| US-20150239906-A1 | Method for Producing cis-5-hydroxy-2-piperidinecarboxylic Acid Derivative, and Method for Purifying cis-5-hydroxy-2-piperidinecarboxylic Acid | UBE CORPORATION (JP) | 2015-08-27 | — | — | US | disclosed |
| EP-2889288-A1 | METHOD FOR PRODUCING cis-5-HYDROXY-2-PIPERIDINECARBOXYLIC ACID DERIVATIVE, AND METHOD FOR PURIFYING cis-5-HYDROXY-2-PIPERIDINECARBOXYLIC ACID | API Corporation (JP) | 2015-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239906-A1 | Method for Producing cis-5-hydroxy-2-piperidinecarboxylic Acid Derivative, and Method for Purifying cis-5-hydroxy-2-piperidinecarboxylic Acid | HCAR2, HCAR1, C5 | FKBP1A 690/4885KLK7 4156/4885POLB 3432/4885 |
| US-10590122-B2 | RAD51 inhibitors | RAD51, MRE11, RAD54L | FKBP1A 1433/4885KLK7 2425/4885POLB 86/4885 |
| US-10336746-B1 | RAD51 inhibitors | RAD51, MRE11, RAD54L | FKBP1A 1433/4885KLK7 2425/4885POLB 86/4885 |
| US-20250082614-A1 | METHODS OF USING RAD51 INHIBITORS FOR TREATMENT OF PANCREATIC CANCER | RAD51, MRE11, RAD52 | FKBP1A 2507/4885KLK7 2384/4885POLB 94/4885 |
| US-20250136591-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | FKBP1A 1433/4885KLK7 2425/4885POLB 86/4885 |
| US-20190194182-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | FKBP1A 1433/4885KLK7 2425/4885POLB 86/4885 |
| US-12064419-B2 | Methods of using RAD51 inhibitors for treatment of pancreatic cancer | RAD51, MRE11, RAD52 | FKBP1A 2507/4885KLK7 2384/4885POLB 94/4885 |
| US-20190077799-A1 | RAD51 Inhibitors | RAD51, MRE11, RAD54L | FKBP1A 1433/4885KLK7 2425/4885POLB 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.